Novartis to Buy Anthos Therapeutics From Blackstone

Novartis to Buy Anthos Therapeutics From Blackstone for Up to $3.1 Billion
The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its cardiovascular pipeline.
Novartis buys Blackstone's Anthos for up to $3.1 billion
By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.
Novartis to Buy Anthos Therapeutics for $925 Million
Novartis AG has agreed to acquire Anthos Therapeutics for $925 million as the European drug giant seeks to bolster its late-stage cardiovascular pipeline.
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases,
Blackstone sells Anthos to Novartis for up to $3.1bn
Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases. It is based in Boston.
Novartis agrees to acquire Anthos for up to $3.1 billion
Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by Blackstone's drug development unit, for up to $3.1 billion, the companies said on Tuesday.
M&A News: Novartis Seals $3.1B Deal to Acquire Anthos
Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. Novartis will pay an
FierceBiotech1h
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate
Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...
Pharmaceutical Technology35m
Novartis signs agreement to acquire Anthos for $925m upfront
Novartis has agreed to acquire Anthos Therapeutics, a Boston-based clinical-stage biopharmaceutical company, for an upfront ...
Novartis2h
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...
MM&M3d
Novartis’ chief marketing officer on the drugmaker’s Super Bowl ad debut
Unlike other brands that release their ads days or weeks ahead of the Big Game, Novartis is waiting to unveil its commercial ...
Super Bowl Highlights Breast Cancer Awareness In Novartis Commercial With Wanda Sykes
The Super Bowl tackled breast cancer awareness in a new Novartis Commercial featuring survivor and comedian Wanda Sykes.
Novartis beats Q4 earnings consensus as drug sales surge
Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...
FiercePharma20h
Novartis debuts €40M viral vector plant in Slovenia, part of €3.5B investment push in the country
Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...
Novartis Wins at the 2025 Kellogg School Super Bowl Advertising Review
Novartis took home the top spot in the 21st Kellogg School Super Bowl Advertising Review with its "Your Attention, Please" ad putting a spotlight on breast health and encouraging cancer screening – ...